Table 2.
Metabolism-related medications
| Medication | Target | Study model | Effect | Refs |
|---|---|---|---|---|
| AZD3965 | MCT-1 |
Male BALB/c, male DBA/2 and female CBA/J mice |
Block lactic acid intake | [58] |
| Leptin | NO/cGMP/PK-G | Swiss albino mice | Inhibit uterine contractions | [87] |
| SGC707 | PRMT3/ADMA/NO | Female CBA/J, male DBA/2 and male BALB/c mice | Inhibit the apoptosis of trophoblast cells | [96] |
| Vitamin D | CBS |
Human blood samples Human placenta samples |
Inhibit inflammatory immune response | [102] |
| Astaxanthin | Nrf2/HO-1 | C57BL/KsJ db/ + mice | Inhibits oxidative stress in the body and enhances antioxidant enzyme activity | [118] |
|
ALA DHLA |
FAK/Src/HIF-1α | Human samples | stimulate Nrf2-dependent gene transcription and inhibit NF-kB activity | [120] |
MCT-1 monocarboxylate transporter protein 1, PK-G protein kinase G, PRMT3 protein l-arginine methyltransferase 3, ADMA asymmetric dimethylarginine, CBS cystathionine beta-synthase, Nrf2 Nuclear factor-erythroid 2 related factor 2, HO-1 Heme Oxygenase-1, ALA alpha lipoic acid, DHLA dihydrolipoic acid, FAK focal adhesion kinase, Src steroid receptor coactivator, HIF-1α Hypoxia inducible factor 1 α